|1.||Hu, Haitang: 3 articles (01/2012 - 10/2010)|
|2.||Kim, D Y: 2 articles (09/2014 - 09/2000)|
|3.||Zhou, Liya: 2 articles (01/2012 - 04/2011)|
|4.||Wang, Ling: 2 articles (01/2012 - 04/2011)|
|5.||Xia, Jielai: 2 articles (01/2012 - 04/2011)|
|6.||Lin, Sanren: 2 articles (01/2012 - 04/2011)|
|7.||Rl, Song: 1 article (11/2015)|
|8.||Liu, Z: 1 article (11/2015)|
|9.||Xu, G X: 1 article (11/2015)|
|10.||Lu, W Q: 1 article (11/2015)|
|1.||Duodenal Ulcer (Curling's Ulcer)
05/07/2014 - "Ilaprazole is a highly effective and safe PPI in the treatment of duodenal ulcers. "
05/07/2014 - "Efficacy of ilaprazole in the treatment of duodenal ulcers: a meta-analysis."
05/07/2014 - "A meta-analysis of randomized controlled trials comparing the efficacy and tolerance of ilaprazole and other PPIs in the treatment of duodenal ulcers was performed. "
01/01/2012 - "Ilaprazole for the treatment of duodenal ulcer: a randomized, double-blind and controlled phase III trial."
10/01/2013 - "In healthy volunteers, as well as in patients with gastric or duodenal ulcers, ilaprazole has not shown clinically relevant changes in hematology and biochemistry testing, nor significant treatment-related adverse symptoms."
02/01/2012 - "The aim of this study was to evaluate the effects and safety of different doses of ilaprazole on healthy volunteers without a Helicobacter pylori infection. "
08/14/2012 - "pylori)infection and compare the eradication rate of ilaprazole versus esoprazole-based regimen. "
08/14/2012 - "[Ilaprazole based bismuth-containing quadruple regimen for the first-line treatment of Helicobacter pylori infection: a multicenter, randomized, controlled clinical study]."
|3.||Gastroesophageal Reflux (GERD)
10/01/2013 - "This review provides an update on the following points: pharmacokinetic profile and metabolism of ilaprazole in relation to its pharmacodynamic properties; comparative data on the pharmacokinetics and pharmacodynamics of ilaprazole with currently available PPIs; and implications for studies on the therapeutic efficacy of ilaprazole in GERD. "
10/01/2013 - "Moreover, further investigations assessing the efficacy of ilaprazole in the management of GERD are required. "
10/01/2013 - "The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment."
09/01/2000 - "A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease."
09/01/2000 - "To evaluate and compare the pharmacodynamic effects of IY-81149 and omeprazole on gastric pH in patients with gastroesophageal reflux disease. "
10/01/2014 - "Ilaprazole at a dose of 3 mg/kg decreased ulcer number and index to the same extent as 20 mg/kg esomeprazole. "
01/01/2012 - "At week 4, the ulcer healing rates were 93.0% in ilaprazole group and 90.8% in omeprazole group (rate difference: 2.2%; 95% confidence interval: -2.8% to 7.2%). "
04/01/2011 - "At week 4, 86.4%, 93.1%, 86.4%, and 89.8% patients treated with 5 mg ilaprazole, 10 mg ilaprazole, 20 mg ilaprazole, and 20 mg omeprazole once daily, respectively had ulcers healed (P=0.59). "
01/01/2009 - "Ilaprazole (IY-81149) is a new proton-pump inhibitor (PPI) not previously studied in human patients with ulcer disease. "
01/01/2009 - "Randomized, parallel, double-blind comparison of the ulcer-healing effects of ilaprazole and omeprazole in the treatment of gastric and duodenal ulcers."
|5.||Stomach Ulcer (Gastric Ulcer)
10/01/2010 - "Ilaprazole is a new proton pump inhibitor designed for the treatment of gastric ulcers, and limited data is available on the metabolism of the drug. "
03/01/2012 - "Ilaprazole is a new proton pump inhibitor, designed for treatment of gastric ulcers, and developed by Il-Yang Pharmaceutical Co (Seoul, Korea). "
01/01/2009 - "Ulcers were successfully healed in 64.29, 67.14, and 63.89% of gastric ulcer patients and 78.85, 83.65, and 78.57% of duodenal ulcer patients after treatment with 20 mg omeprazole, 5 mg ilaprazole, and 10 mg ilaprazole, respectively. "
|1.||Proton Pump Inhibitors
|4.||Proton Pumps (Proton Pump)